If a supplied lot fails agreed specifications, we’ll replace it at no cost or refund its purchase price in full.
Quality test failed? Free replacement or full refund.
Off-spec? Free replacement or full refund.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epithalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
Cagrilintide + Semaglutide combination
Supply and ordering
Ask sales about CagriSema availability, order quantities, packaging, and batch documentation. Include other catalog items in the same inquiry if you are planning a combined or recurring order.
Overview
CagriSema is a fixed-combination preparation of the long-acting amylin analog Cagrilintide and the GLP-1 receptor agonist Semaglutide, currently in Novo Nordisk's Phase 3 REDEFINE clinical-development program for chronic weight management. The combination represents the next-generation evolution of GLP-1-based weight-management pharmacology by adding the amylin-axis mechanism (acting on the area postrema and calcitonin-receptor family) to the GLP-1 receptor mechanism, producing additive weight-reduction signals that exceed Semaglutide monotherapy in head-to-head dose-equivalent comparisons. The standard ratio is 1:1 by mass of Cagrilintide to Semaglutide, though custom ratios are available for research applications studying ratio-dependent biology. PeptideXpo supplies CagriSema as a pre-blended co-lyophilized product to a ≥99.0% HPLC purity specification for each component, with the measured ratio available on request rather than inferred from total mass. Co-lyophilization is preferred over solution-phase mixing because amylin-class peptides have surface-mediated aggregation sensitivity in dilute solution. The batch COA reports both component purities individually by HPLC with MS identity; the measured ratio in the released vial is available on request and listed on the COA when tested. Three fill sizes (5, 10, 20 mg total) cover both research and compounding workflows.
Who buys this, and why
Custom-blend buyers are almost always OEM clients building a branded product around a specific ratio of two or more peptides. The development workflow is collaborative: ratio target, analytical method to verify it, stability protocol in the chosen carrier, and packaging selection are all defined in the OEM brief before the first commercial run. Sample-stage volumes are usually 5-10 g of finished blend; commercial MOQ depends on the components.
Primary buyer fit: 503A / 503B compounding pharmacies and academic and contract research laboratories.
Specifications
Also available as a nasal spray (US stock)
Besides lyophilized vials, CagriSema is stocked in the US as a ready-to-use nasal spray.
Documentation available on request
Each picture is a low-resolution preview of a report's first page, with batch and report numbers covered. For the full, clear report, ask our sales team, naming the product and strength.
Batch COACagriSema 2.5 mg + 2.5 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Batch COACagriSema 5 mg + 5 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Batch COACagriSema 10 mg + 10 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Independent test fails? Full refund. How it works
Regulatory note
Investigational combination product (Novo Nordisk REDEFINE program); not approved as a finished drug at the time of writing. Ask sales for the matching batch COA and agree any component-level data or ratio verification required for the offered lot.
Selected literature
Frequently asked questions
Amylin-class peptides (including Cagrilintide) have a documented sensitivity to surface-mediated aggregation when held in dilute aqueous solution, the same biology that drives native amylin to form fibrils in the pancreas under disease conditions. Co-lyophilizing Cagrilintide with Semaglutide produces a stable solid-state product where the ratio is locked in by the lyophilization step and surface-aggregation issues don't manifest until reconstitution at point of use. Solution-phase mixing of separately-purchased Cagrilintide and Semaglutide vials is operationally possible but produces variable ratios and degraded amylin component over time. The pre-blended product also simplifies the documentation chain: a single COA certifies both components and the verified ratio.
Cagrilintide acts on the amylin and calcitonin receptor family at the area postrema, contributing to satiety signaling and gastric-emptying delay. Semaglutide acts on the GLP-1 receptor in the arcuate nucleus and peripheral tissues, contributing to appetite suppression and insulinotropic effects. The two signaling axes are anatomically and pharmacologically distinct, they converge on common downstream effects (reduced food intake, weight reduction) but through parallel rather than redundant pathways. The clinical-program rationale is that combining the two produces additive weight-reduction beyond what either monotherapy can achieve at maximal tolerable doses, which the Phase 2 REDEFINE-2 data supported.
Yes. CagriSema is also stocked as a ready-to-use nasal spray (10 mg) in 10 mL or 20 mL bottles, from 10 bottles of each. These orders ship from our US stock; ask our sales team for details and a quote.
Send any vial from your order to an independent laboratory of your choice. If the report shows the product does not meet the specification on its COA — purity below the stated minimum, or an identity that does not match — share the report with our sales team and we refund that product in full.
Related peptides
Long-acting amylin analog
Nasal spray available
GLP-1 receptor agonist
Nasal spray available
GIP / GLP-1 dual receptor agonist
Nasal spray available
